首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Novel approach of fragment-based lead discovery applied to renin inhibitors
Institution:1. Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, 2-26-1, Muraoka-higashi, Fujisawa, Kanagawa 251-8555, Japan;2. Takeda California, Inc., 10410, Science Center Drive, San Diego, CA 92121, United States;1. Institute for Pharmacy and Food Chemistry, University of Wuerzburg, Am Hubland, Wuerzburg 97074 , Germany;2. Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400030, PR China;3. Institute for Pharma Technology, University of Applied Sciences Northwestern Switzerland, Gruendenstrasse 40, Muttenz 4132, Switzerland;1. Laboratoire de Chimie des Matériaux, Faculté des Sciences de Bizerte, Université de Carthage, Zarzouna 7021, Tunisia;2. Unité de Service Commun Spectromètre de Surfaces, Faculté des Sciences de Bizerte, Université de Carthage, Zarzouna 7021, Tunisia;3. Department of Chemical and Pharmaceutical Sciences and Center for Structural Diffractometry, Via Fossato di Mortara 17, I-44121 Ferrara, Italy;4. Laboratoire de Chimie Organométallique de Surface (LCOMS), Ecole Supérieure de Chimie Physique Electronique, 69626 Villeurbanne Cedex, France
Abstract:A novel approach was conducted for fragment-based lead discovery and applied to renin inhibitors. The biochemical screening of a fragment library against renin provided the hit fragment which showed a characteristic interaction pattern with the target protein. The hit fragment bound only to the S1, S3, and S3SP (S3 subpocket) sites without any interactions with the catalytic aspartate residues (Asp32 and Asp215 (pepsin numbering)). Prior to making chemical modifications to the hit fragment, we first identified its essential binding sites by utilizing the hit fragment’s substructures. Second, we created a new and smaller scaffold, which better occupied the identified essential S3 and S3SP sites, by utilizing library synthesis with high-throughput chemistry. We then revisited the S1 site and efficiently explored a good building block attaching to the scaffold with library synthesis. In the library syntheses, the binding modes of each pivotal compound were determined and confirmed by X-ray crystallography and the library was strategically designed by structure-based computational approach not only to obtain a more active compound but also to obtain informative Structure Activity Relationship (SAR). As a result, we obtained a lead compound offering synthetic accessibility as well as the improved in vitro ADMET profiles. The fragments and compounds possessing a characteristic interaction pattern provided new structural insights into renin’s active site and the potential to create a new generation of renin inhibitors. In addition, we demonstrated our FBDD strategy integrating highly sensitive biochemical assay, X-ray crystallography, and high-throughput synthesis and in silico library design aimed at fragment morphing at the initial stage was effective to elucidate a pocket profile and a promising lead compound.
Keywords:Fragment-based drug discovery (FBDD)  High-throughput synthetic chemistry  Structure-based drug design (SBDD)  Renin inhibitor  Crystal structure
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号